Tag: Eli Lilly
Eli Lilly Reports 48% Revenue Growth in Q2 2026 and Raises Full-Year Guidance
Eli Lilly and Company announced its financial results for the second quarter of 2026, delivering worldwide revenue of $23.0 billion,a 48% increase compared with the same...
Eli Lilly Acquires AtaiBeckley to Accelerate Innovative Depression Treatments
Eli Lilly and Company and AtaiBeckley Inc. announced a agreement for Lilly to acquire AtaiBeckley. The transaction features cash consideration of $6.75 per share,...
Lilly’s Obesity Portfolio Wins Full U.S. Insurance Coverage, Reshaping the GLP-1 Landscape
In a pivotal shift for the obesity treatment market, Eli Lilly and Company (NYSE: LLY) has secured formulary coverage across all three of America's...
Eli Lilly Expands Oncology Ambitions with Up to $2.3 Billion Ajax Therapeutics Acquisition
Eli Lilly has announced a major strategic move to strengthen its oncology portfolio through the acquisition of Ajax Therapeutics in a deal valued at...
Eli Lilly Expands Oncology Pipeline with Kelonia Buyout, Targets Next-Gen CAR-T Therapy
In a strategic move set to reshape the future of cancer treatment, Eli Lilly and Company has announced its acquisition of Kelonia Therapeutics in...
